This guide helps qualified organizations structure questions, documents, controls, and professional handoffs. It does not determine legal status or replace advice from authorized legal, regulatory, pharmacy, medical, customs, or quality professionals.
Classify the article before selecting the import code
Import planning begins with the actual article and intended use, not with a tariff description chosen for convenience. Determine whether the shipment contains a research material, API, bulk drug substance, finished dosage form, approved drug, investigational article, or another regulated product. Document the basis and obtain qualified advice for ambiguous cases.
The classification should match commercial documents, labeling, website claims, customer records, and the physical product. A shipment described as a laboratory chemical while surrounding evidence indicates therapeutic human use creates a material inconsistency that a short disclaimer may not resolve.
Map the parties and regulatory identifiers
FDA import review uses information about the declared manufacturer, importer or consignee, product description, intended use, and applicable affirmations of compliance. For human drugs, FDA may verify establishment registration, drug listing, application information, labeling, and CGMP status as applicable.
Create a party map identifying the actual manufacturer, testing laboratory, repackager, relabeler, foreign exporter, importer of record, consignee, customs broker, carrier, and final receiving organization. Confirm that names and addresses are current and consistent across source records and entry documents.
- Exact manufacturer and site, not only the commercial seller or marketplace.
- Importer of record, consignee, broker, quality contact, and final receiver.
- Applicable registration, listing, application, investigational, or other identifiers.
- Product description, quantity, packaging, country of origin, and intended-use support.
Assemble an entry-support package before departure
Complete and accurate electronic information can help FDA assess an entry, while incomplete or inconsistent information may lead to manual review, requests, detention, or refusal. The import file should be ready before the shipment leaves origin, not assembled after a notice arrives.
The package may include commercial invoice, packing list, airway bill, manufacturer information, specifications, certificate, label images, registration or listing support, application information when applicable, intended-use statement, purchase order, and qualified regulatory analysis. The exact set depends on the article.
Plan for examination, delay, and controlled storage
A route plan should account for the possibility of document review, examination, sampling, or detention. Temperature-sensitive material needs sufficient packaging duration, monitoring, and contingency capacity for a longer-than-planned import process. The broker and quality team should know who can answer FDA questions and provide records promptly.
Receiving readiness matters as much as entry release. Confirm delivery appointments, storage, monitoring review, quarantine status, inspection, reconciliation, and the process for handling damaged packages or temperature excursions before the shipment is released into use.
Keep a complete import decision file
Retain the classification basis, professional advice, entry data, communications, FDA notices, transport records, receipt inspection, and final disposition. Use post-entry reviews to correct recurring data mismatches and improve future submissions.
Pharma Americas Group coordinates documentation, supplier communications, logistics handoffs, and receiving requirements for qualified organizations. We work alongside the client’s customs broker, counsel, regulatory professionals, and quality unit; we do not provide customs classification, legal opinions, or guarantees of admission.
Frequently asked questions
Are all imported peptides treated the same by FDA?
No. Requirements depend on the article, intended use, regulatory category, manufacturer, pathway, claims, and destination. A product may be reviewed differently as a research material, API, compounded-drug component, or finished drug.
Can a customs broker determine whether a peptide is legally admissible?
A broker can help submit entry data, but the importer remains responsible for compliance. Classification and admissibility questions should be resolved with qualified legal, regulatory, and customs professionals.
Why do peptide imports receive manual review?
FDA explains that entries may be routed for human review when risk is higher or compliance cannot be verified, including incomplete or inconsistent manufacturer, registration, application, labeling, or other entry information.
Sources and evidence
These primary government and agency resources informed the article’s operating perspective. Regulations, guidance, agency lists, and enforcement information can change. Review the current source and obtain qualified advice for the specific program.
This article provides general operational information current as of July 23, 2026. It is not medical, legal, regulatory, compliance, customs, pharmacy, or quality advice. Requirements vary by product, organization, intended use, pathway, transaction, and jurisdiction and may change. Consult qualified professionals and current official authorities before acting.
Corrections and updates
If you identify a factual error, outdated authority, broken source, or material omission, email the editorial review team. Include the article title, the statement at issue, supporting evidence, and your contact information. Submissions are evaluated against primary sources and the article's stated scope.
A review date changes only after substantive re-evaluation. Material corrections are identified on the affected article; routine copy, formatting, or link maintenance may be corrected without a separate note.
